Antifungal Drugs Market Analysis By Drug Class (Azoles, Echinocandins, Polyenes, Allyamines), By Indication (Dermatophytosis, Aspergillosis, Candidiasis) And Segment Forecasts, 2014 - 2025

  • ID: 3989884
  • Report
  • 110 pages
  • Grand View Research
1 of 3
The global antifungal drugs market was valued at USD 10.7 billion in 2015 and is expected to reach a value of USD 12.6 billion by 2025. The increasing incidence of fungal infections worldwide is the key contributing factor for the growth of the antifungal drugs market in the coming years. Rising adoption of immunosuppressive andantineoplastic agents, prosthetic devices and grafts, and broad-spectrum antibiotics have resulted in the increasing incidence of fungal infections in the recent years.

The growing geriatric population prone to infectious diseases and higher prevalence of chronic conditions, including HIV and cancer, are further contributing toward the rising demand for antifungals to treat opportunistic fungal infections over the forecast period. The large demand for these fungistatic agents is due to the nature of fungal infections, which are difficult to diagnose, yielding high mortality and morbidity rates.

Further Key Findings from the Study Suggest:

Echinocandins segment is anticipated to exhibit lucrative growth owing to their cell wall-specific fungicidal property coupled with their broad-spectrum activity against Aspergillus and Candida species without cross-resistance risks

Candidiasis indication segment is anticipated to witness the fastest CAGR over the forecast period due to the increasing drug resistance of the Candida speciesto Azoles

North America held the largest market share as of 2015, which is attributable to higher awareness levels pertaining to the treatment of fungal infection and presence of target diseases in the population

Asia pacific is predicted to exhibit the fastest growth due to improving healthcare facilities coupled with rising government initiatives to create awareness of infectious diseases amongst the population

The companies are focusing on the development of effective therapeutic agents for the treatment of systemic fungal infections in immune-compromised patients

Numerous ongoing public-private partnership agreements in the pharmaceutical industry for the development of novel therapeutics is predicted to provide this market with lucrative growth opportunities

For example, the public-private partnership, namely Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator is anticipated to provide USD 44 million in 2016 and around USD 350 million in the coming 5 years to boost the R&D pipeline

The partners involved in this partnership are the U.S. Department of Health and Human Services, the Antimicrobial Resistance Centrein England, and Boston University School of Law
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1 Research Methodology & Scope
1.1 Region Wise Market Calculation
1.1.1 Region Wise Market: Base Estimates
1.1.2 Global Market: CAGR Calculation
1.2 Region based segment share calculation
1.3 List of Secondary Sources
2 Executive Summary
3 Market VariabAllyamines, Trends& Scope
3.1 Market segmentation & scope
3.1.1 Market Driver Analysis
3.1.1.1 Increasing incidences of fungal infections
3.1.1.2 Increasing R&D pertaining to the development of novel drugs
3.1.1.3 Increasing awareness levels
3.1.2 Market Restraint Analysis
3.1.2.1 Resistance to antifungal drugs
3.1.2.2 Presence of generic competition
3.2 Penetration & Growth Prospect Mapping
3.3 Antifungal Drugs - PESTLE Analysis
3.4 Industry Analysis - Porter’s
4 Market Categorization 1: Drug Class Estimates & Trend Analysis
4.1 Antifungal Drugs Market: Drug Class Movement Analysis
4.2 AzoAllyamines
4.2.1 AzoAllyamines market, 2014 - 2025 (USD Million)
4.3 Echinocandins
4.3.1 Echinocandins market, 2014 - 2025 (USD Million)
4.4 Polyenes
4.4.1 Polyenes market, 2014 - 2025 (USD Million)
4.5 Allylamines
4.5.1 Allylamines market, 2014 - 2025 (USD Million)
4.6 Others
4.6.1 Others market, 2014 - 2025 (USD Million)
5 Market Categorization : Indication Estimates & Trend Analysis
5.1 Antifungal Drugs Market: indication Movement Analysis
5.2 Dermatophytosis
5.2.1 Dermatophytosis market, 2014 - 2025 (USD Million)
5.3 Aspergillosis
5.3.1 Aspergillosis market, 2014 - 2025 (USD Million)
5.4 Candidiasis
5.4.1 Candidiasis market, 2014 - 2025 (USD Million)
5.5 Others
5.5.1 Others market, 2014 - 2025 (USD Million)
6 Market Categorization : Regional Estimates & Trend Analysis, by Drug Class and Indications
6.1 Antifungal Drugs market share by region, 2015 & 2024
6.2 North America
6.2.1 North America antifungal drugs market, 2014 - 2025 (USD Million)
6.2.2 U.S.
6.2.2.1 U.S. antifungal drugs market, 2014 - 2025 (USD Million)
6.2.3 Canada
6.2.3.1 Canada antifungal drugs market, 2014 - 2025 (USD Million)
6.3 Europe
6.3.1 Europe antifungal drugs market, 2014 - 2025 (USD Million)
6.3.2 UK
6.3.2.1 UK antifungal drugs market, 2014 - 2025 (USD Million)
6.3.3 Germany
6.3.3.1 Germany antifungal drugs market, 2014 - 2025 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific antifungal drugs market, 2014 - 2025 (USD Million)
6.4.2 Japan
6.4.2.1 Japan antifungal drugs market, 2014 - 2025 (USD Million)
6.4.3 China
6.4.3.1 China antifungal drugs market, 2014 - 2025 (USD Million)
6.4.4 India
6.4.4.1 India antifungal drugs market, 2014 - 2025 (USD Million)
6.5 Latin America
6.5.1 Latin America antifungal drugs market, 2014 - 2025 (USD Million)
6.5.2 Brazil
6.5.2.1 Brazil antifungal drugs market, 2014 - 2025 (USD Million)
6.5.3 Mexico
6.5.3.1 Mexico antifungal drugs market, 2014 - 2025 (USD Million)
6.6 MEA
6.6.1 MEA antifungal drugs market, 2014 - 2025 (USD Million)
6.6.2 South Africa
6.6.2.1 South Africa antifungal drugs market, 2014 - 2025 (USD Million)
7 Competitive Landscape
7.1 Strategy framework
7.2 Market participation categorization
7.3 Company Profiles
7.3.1 Novartis
7.3.1.1 Company Overview
7.3.1.2 Financial Performance
7.3.1.3 Product Benchmarking
7.3.1.4 Strategic Initiatives
7.3.2 Pfizer Inc.
7.3.2.1 Company Overview
7.3.2.2 Financial Performance
7.3.2.3 Product Benchmarking
7.3.2.4 Strategic Initiatives
7.3.3 Bayer Healthcare
7.3.3.1 Company Overview
7.3.3.2 Financial Performance
7.3.3.3 ProductBenchmarking
7.3.3.4 Strategic Initiatives
7.3.4 Sanofi-Aventis
7.3.4.1 Company Overview
7.3.4.2 Financial Performance
7.3.4.3 Product Benchmarking
7.3.4.4 Strategic Initiatives
7.3.5 Merck & Co. Inc.
7.3.5.1 Company Overview
7.3.5.2 Financial Performance
7.3.5.3 Product Benchmarking
7.3.5.4 Strategic Initiatives
7.3.6 GlaxoSmithKline
7.3.6.1 Company Overview
7.3.6.2 Financial Performance
7.3.6.3 Product Benchmarking
7.3.7 Abbott Laboratories
7.3.7.1 Company Overview
7.3.7.2 Financial Performance
7.3.7.3 Product Benchmarking
7.3.7.4 Strategic Initiatives
7.3.8 Glenmark Pharmaceuticals Ltd
7.3.8.1 Company Overview
7.3.8.2 Financial Performance
7.3.8.3 Product Benchmarking
7.3.8.4 Strategic Initiatives
7.3.9 Enzon Pharmaceuticals
7.3.9.1 Company Overview
7.3.9.2 Financial Performance
7.3.9.3 Product Benchmarking
7.3.9.4 Strategic Initiatives
7.3.10 ID Sigma-Aldrich Corporation
7.3.10.1 Company Overview
7.3.10.2 Financial Performance
7.3.10.3 Product Benchmarking
7.3.10.4 Strategic Initiatives
7.3.11 Astellas Pharma Inc
7.3.11.1 Company Overview
7.3.11.2 Financial Performance
7.3.11.3 Product Benchmarking
7.3.11.4 Strategic Initiatives

List of Tables

Table 1 North America antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
Table 2 North America antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
Table 3 U.S. antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
Table 4 U.S. antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
Table 5 Canada antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
Table 6 Canada antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
Table 7 Europe antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
Table 8 Europe antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
Table 9 UK antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
Table 10 UK antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
Table 11 Germany antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
Table 12 Germany antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
Table 13 Asia Pacific antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
Table 14 Asia Pacific antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
Table 15 Japan antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
Table 16 Japan antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
Table 17 China antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
Table 18 China antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
Table 19 India antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
Table 20 India antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
Table 21 Latin America antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
Table 22 Latin America antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
Table 23 Brazil antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
Table 24 Brazil antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
Table 25 Mexico antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
Table 26 Mexico antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
Table 27 MEA antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
Table 28 MEA antifungal drugs market, by Indications, 2014 - 2025 (USD Million)
Table 29 South Africa antifungal drugs market, by drug class, 2014 - 2025 (USD Million)
Table 30 South Africa antifungal drugs market, by Indications, 2014 - 2025 (USD Million)

List of Figures

Figure 1 Market summary
Figure 2 Market trends & outlook
Figure 3 Market segmentation & scope
Figure 4 Market driver relevance analysis (Current & future impact)
Figure 5 U.S. FDA ADR reports, 2006-2015
Figure 6 Market restraint relevance analysis (Current & future impact)
Figure 7 Penetration & Growth Prospect Mapping
Figure 8 Antifungal Drugs PESTLE Analysis
Figure 9 Porter’s Five Forces Analysis
Figure 10 Antifungal Drugs market drug class outlook key takeaways
Figure 11 Antifungal Drugs market: Drug class movement analysis
Figure 12 AzoAllyamines market, 2014 - 2025 (USD Million)
Figure 13 Echinocandins market, 2014 - 2025 (USD Million)
Figure 14 Polyenes market, 2014 - 2025 (USD Million)
Figure 15 Allylamines market, 2014 - 2025 (USD Million)
Figure 16 Others market, 2014 - 2025 (USD Million)
Figure 17 Antifungal Drugs market indication outlook key takeaways
Figure 18 Antifungal Drugs market: Indications movement analysis
Figure 19 Dermatophytosis market, 2014 - 2025 (USD Million)
Figure 20 Aspergillosis market, 2014 - 2025 (USD Million)
Figure 21 Candidiasis market, 2014 - 2025 (USD Million)
Figure 22 Others market, 2014 - 2025 (USD Million)
Figure 23 Regional marketplace: Key takeaways
Figure 24 Regional outlook, 2015 & 2024
Figure 25 North America antifungal drugs market, 2014 - 2025 (USD Million)
Figure 26 U.S. antifungal drugs market, 2014 - 2025 (USD Million)
Figure 27 Canada antifungal drugs market, 2014 - 2025 (USD Million)
Figure 28 Europe antifungal drugs market, 2014 - 2025 (USD Million)
Figure 29 UK antifungal drugs market, 2014 - 2025 (USD Million)
Figure 30 Germany antifungal drugs market, 2014 - 2025 (USD Million)
Figure 31 Asia Pacific antifungal drugs market, 2014 - 2025 (USD Million)
Figure 32 Japan antifungal drugs market, 2014 - 2025 (USD Million)
Figure 33 China antifungal drugs market, 2014 - 2025 (USD Million)
Figure 34 India antifungal drugs market, 2014 - 2025 (USD Million)
Figure 35 Latin America antifungal drugs market, 2014 - 2025 (USD Million)
Figure 36 Brazil antifungal drugs market, 2014 - 2025 (USD Million)
Figure 37 Mexico antifungal drugs market, 2014 - 2025 (USD Million)
Figure 38 MEA antifungal drugs market, 2014 - 2025 (USD Million)
Figure 39 South Africa antifungal drugs market, 2014 - 2025 (USD Million)
Figure 40 Strategy framework
Figure 41 Participant categorization
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll